1Y Target$46.73Near-term target
5Y Target$57.91Compound horizon
10Y Target$73.91Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev+12.2%TTM YoYB+Revenue +12.2% — above sector median, healthy trajectory · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.07AD/E 0.07 — essentially debt-free, pristine balance sheet
P/E12.0xB+P/E 12.0 — at or below S&P median, reasonable
PEG0.98proxyB+PEG 0.98 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Banking · market cap $1.6b. 4% off the 52-week high of $45.00. Revenue growing +12%, comfortably above the S&P median. PEG 0.98 — paying under fair value for the growth rate.
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.
Risk
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Horizon
1-3 yr $46.73 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $57.91 at ~6% CAGR — dividend + buyback compounding. 10 yr $73.91 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.